Negro Francesco
Divisions of Gastroenterology and hepatology, Geneva University Hospitals, Geneva, Switzerland; Divisions of Clinical pathology, Geneva University Hospitals, Geneva, Switzerland.
J Hepatol. 2021 Apr;74(4):952-963. doi: 10.1016/j.jhep.2020.11.040. Epub 2020 Dec 1.
Treatment of hepatitis C with direct-acting antivirals is safe and highly efficacious, resulting in viral clearance (sustained virological response [SVR]) in the vast majority of patients. Although SVR is mostly permanent and associated with a significant reduction of liver morbidity and mortality, some patients may still suffer from a major risk of progressive liver damage, potentially leading to severe complications - including liver decompensation, hepatocellular carcinoma and death. This concise review discusses some of the most important features of residual liver disease in patients with chronic hepatitis C who have achieved SVR after antiviral therapy.
使用直接作用抗病毒药物治疗丙型肝炎是安全且高效的，绝大多数患者可实现病毒清除（持续病毒学应答 [SVR]）。尽管SVR大多是永久性的，且与肝脏发病率和死亡率的显著降低相关，但一些患者仍可能面临进行性肝损伤的重大风险，这可能导致严重并发症，包括肝失代偿、肝细胞癌和死亡。本简要综述讨论了慢性丙型肝炎患者在抗病毒治疗后实现SVR后残留肝病的一些最重要特征。
